PTC THERAPEUTICS, INC. (PTCT) Form 8-K — Jul 30, 2026
PTC Therapeutics reported a strong second quarter with total revenue of $361 million, marking a significant turnaround to profitability with net income of $83.5 million compared to a net loss of $64.8 million in the prior year. The company raised its full-year 2026 revenue guidance to $1.18 to $1.28 billion, driven by the continued robust uptake of Sephience, which generated $151 million in Q2 revenue. In addition to the financial results, the company announced the appointment of Hege Sollie-Zetlmayer to its board of directors, effective immediately. Ms.
Key figures
- Eps
- 0.92
- Revenue
- 360519000
- Guidance
- Total revenue $1.18 to $1.28 billion; Product revenue $850 to $950 million
- Net Income
- 83496000
- Total Debt
- 590970000
- Revenue Yoy
- 101.6%
- Cash Position
- 2,229,082,000
- Deal Value Usd
- 50000000
- Emflaza Revenue
- 24600000
- Product Revenue
- 238819000
- Sophience Revenue
- 151300000
- Shares Outstanding
- 83327286
- Translarna Revenue
- 42200000
- Evrysdi Royalty Revenue
- 71100000
- Cash And Marketable Securities
- 2229082000
Price after filing
Close on the filing date to close N calendar days later (from $75.39). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.